PubMed

Delayed-Release Oral Mesalamine 4.8 g/day (800-mg tablet) is Effective for Patients with Moderately Active Ulcerative Colitis.

Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB.

Gastroenterology. 2009 Sep 18. [Epub ahead of print]PMID: 19766640 [PubMed - as supplied by publisher]Related articles

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.

D'Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Schölmerich J, Hanauer S, Sandborn WJ; IOIBD Membership.

Inflamm Bowel Dis. 2009 Oct;15(10):1599-604.PMID: 19653291 [PubMed - in process]Related articles

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.

Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF.

Gastroenterology. 2009 Oct;137(4):1250-60; quiz 1520. Epub 2009 Jul 28.PMID: 19596014 [PubMed - indexed for MEDLINE]Related articles

Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.

Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S.

Am J Gastroenterol. 2009 Aug;104(8):1976-83. Epub 2009 May 26.PMID: 19471252 [PubMed - indexed for MEDLINE]Related articles

A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.

Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG.

Hypertension. 2009 Apr;53(4):646-53. Epub 2009 Feb 23.PMID: 19237683 [PubMed - indexed for MEDLINE]Related articles

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

Am J Gastroenterol. 2008 Dec;103(12):3132-41. Epub 2008 Oct 3. Erratum in: Am J Gastroenterol. 2009 Jul;104(7):1894. PMID: 18853973 [PubMed - indexed for MEDLINE]Related articles

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.

Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P.

Gastroenterology. 2008 Nov;135(5):1493-9. Epub 2008 Aug 3.PMID: 18848553 [PubMed - indexed for MEDLINE]Related articles

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.

Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Cohen A, Bitton A, Baker J, Dubé R, Landau SB, Vandervoort MK, Parikh A.

Clin Gastroenterol Hepatol. 2008 Dec;6(12):1370-7. Epub 2008 Oct 1. Erratum in: Clin Gastroenterol Hepatol. 2009 Apr;7(4):494. PMID: 18829392 [PubMed - indexed for MEDLINE]Related articles

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn WJ.

Clin Gastroenterol Hepatol. 2008 Nov;6(11):1218-24. Epub 2008 Sep 17.PMID: 18799360 [PubMed - indexed for MEDLINE]Related articles

Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.

Thia KT, Sandborn WJ, Lewis JD, Loftus EV Jr, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE.

Am J Gastroenterol. 2008 Dec;103(12):3123-31.PMID: 18786111 [PubMed - indexed for MEDLINE]Related articles

A randomized trial of arthroscopic surgery for osteoarthritis of the knee.

Kirkley A, Birmingham TB, Litchfield RB, Giffin JR, Willits KR, Wong CJ, Feagan BG, Donner A, Griffin SH, D'Ascanio LM, Pope JE, Fowler PJ.

N Engl J Med. 2008 Sep 11;359(11):1097-107. Erratum in: N Engl J Med. 2009 Nov 12;361(20):2004. PMID: 18784099 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P; Ustekinumab Crohn's Disease Study Group.

Gastroenterology. 2008 Oct;135(4):1130-41. Epub 2008 Jul 17.PMID: 18706417 [PubMed - indexed for MEDLINE]Related articles

Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study.

Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ.

Inflamm Bowel Dis. 2009 Jan;15(1):17-24.PMID: 18668682 [PubMed - indexed for MEDLINE]Related articles

Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials.

Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, Cohen A, Dallaire C, Ponich TP, McDonald JW, Hébuterne X, Paré P, Klvana P, Niv Y, Ardizzone S, Alexeeva O, Rostom A, Kiudelis G, Spleiss J, Gilgen D, Vandervoort MK, Wong CJ, Zou GY, Donner A, Rutgeerts P.

JAMA. 2008 Apr 9;299(14):1690-7.PMID: 18398081 [PubMed - indexed for MEDLINE]Related articlesFree article

Review and clinical perspectives for the use of infliximab in ulcerative colitis.

Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH.

Can J Gastroenterol. 2008 Mar;22(3):261-72. Review.PMID: 18354755 [PubMed - indexed for MEDLINE]Related articlesFree article

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club.

Lancet. 2008 Feb 23;371(9613):660-7.PMID: 18295023 [PubMed - indexed for MEDLINE]Related articles

Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.

Feagan BG, Sandborn WJ, Hass S, Niecko T, White J.

Am J Gastroenterol. 2007 Dec;102(12):2737-46.PMID: 18042106 [PubMed - indexed for MEDLINE]Related articles

Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.

Sandborn WJ, Feagan BG, Lichtenstein GR.

Aliment Pharmacol Ther. 2007 Oct 1;26(7):987-1003. Review.PMID: 17877506 [PubMed - indexed for MEDLINE]Related articlesFree article

Certolizumab pegol for the treatment of Crohn's disease.

Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S; PRECISE 1 Study Investigators.

N Engl J Med. 2007 Jul 19;357(3):228-38.PMID: 17634458 [PubMed - indexed for MEDLINE]Related articlesFree article

Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's disease and measures of utility.

Buxton MJ, Lacey LA, Feagan BG, Niecko T, Miller DW, Townsend RJ.

Value Health. 2007 May-Jun;10(3):214-20.PMID: 17532814 [PubMed - indexed for MEDLINE]Related articles

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.

Gastroenterology. 2007 May;132(5):1672-83. Epub 2007 Mar 21.PMID: 17484865 [PubMed - indexed for MEDLINE]Related articles

Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.

Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, Radford-Smith G, Xu S, Eisenberg D, Olson A, Colombel JF.

Inflamm Bowel Dis. 2007 Sep;13(9):1135-40.PMID: 17476675 [PubMed - indexed for MEDLINE]Related articlesFree article

A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty.

Wong CJ, Vandervoort MK, Vandervoort SL, Donner A, Zou G, MacDonald JK, Freedman J, Karkouti K, MacDonald SJ, Feagan BG.

Transfusion. 2007 May;47(5):832-41.PMID: 17465948 [PubMed - indexed for MEDLINE]Related articles

The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.

Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB.

Am J Gastroenterol. 2007 Apr;102(4):794-802. Epub 2007 Feb 23. Erratum in: Am J Gastroenterol. 2007 Jun;102(6):1338. PMID: 17324131 [PubMed - indexed for MEDLINE]Related articles

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR.

Gastroenterology. 2007 Feb;132(2):763-86. Epub 2006 Dec 20. Review. No abstract available. PMID: 17258735 [PubMed - indexed for MEDLINE]Related articles

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ.

Clin Gastroenterol Hepatol. 2006 May;4(5):621-30. Erratum in: Clin Gastroenterol Hepatol. 2006 Jul;4(7):931. PMID: 16678077 [PubMed - indexed for MEDLINE]Related articles

Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.

Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ.

Am J Gastroenterol. 2006 May;101(5):1030-8.PMID: 16606351 [PubMed - indexed for MEDLINE]Related articles

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.

Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS.

Gut. 2006 Nov;55(11):1568-74. Epub 2006 Apr 7.PMID: 16603634 [PubMed - indexed for MEDLINE]Related articlesFree article

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A.

Aliment Pharmacol Ther. 2006 Mar 1;23(5):617-28.PMID: 16480401 [PubMed - indexed for MEDLINE]Related articlesFree article

Infliximab for induction and maintenance therapy for ulcerative colitis.

Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF.

N Engl J Med. 2005 Dec 8;353(23):2462-76. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. PMID: 16339095 [PubMed - indexed for MEDLINE]Related articlesFree article

Natalizumab induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group.

N Engl J Med. 2005 Nov 3;353(18):1912-25.PMID: 16267322 [PubMed - indexed for MEDLINE]Related articlesFree article

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.

Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR.

Am J Gastroenterol. 2005 Aug;100(8):1780-7.PMID: 16086715 [PubMed - indexed for MEDLINE]Related articles

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK.

N Engl J Med. 2005 Jun 16;352(24):2499-507.PMID: 15958805 [PubMed - indexed for MEDLINE]Related articlesFree article

Cyclosporine for induction of remission in Crohn's disease.

McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000297. Review.PMID: 15846602 [PubMed - indexed for MEDLINE]Related articles

Unemployment and disability in patients with moderately to severely active Crohn's disease.

Feagan BG, Bala M, Yan S, Olson A, Hanauer S.

J Clin Gastroenterol. 2005 May-Jun;39(5):390-5.PMID: 15815207 [PubMed - indexed for MEDLINE]Related articles

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.

Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):373-84.PMID: 15709987 [PubMed - indexed for MEDLINE]Related articlesFree article

A review of activity indices and end points for clinical trials in children with Crohn's disease.

Griffiths AM, Otley AR, Hyams J, Quiros AR, Grand RJ, Bousvaros A, Feagan BG, Ferry GR.

Inflamm Bowel Dis. 2005 Feb;11(2):185-96. Review.PMID: 15677913 [PubMed - indexed for MEDLINE]Related articles

Methotrexate for induction of remission in refractory Crohn's disease.

Alfadhli AA, McDonald JW, Feagan BG.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003459. Review.PMID: 15674908 [PubMed - indexed for MEDLINE]Related articles

Endoscopic scoring system for Crohn's disease: viva the evolution!

Feagan BG.

Gastrointest Endosc. 2004 Oct;60(4):590-1. No abstract available. PMID: 15472684 [PubMed - indexed for MEDLINE]Related articles

High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study.

Mow WS, Landers CJ, Steinhart AH, Feagan BG, Croitoru K, Seidman E, Greenberg GR, Targan SR.

Dig Dis Sci. 2004 Aug;49(7-8):1280-6.PMID: 15387358 [PubMed - indexed for MEDLINE]Related articles

The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain.

Sandborn WJ, Feagan BG.

Gastroenterology. 2004 Sep;127(3):990-3. No abstract available. PMID: 15362055 [PubMed - indexed for MEDLINE]Related articles

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.

Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J.

Gut. 2004 Oct;53(10):1485-93.PMID: 15361500 [PubMed - indexed for MEDLINE]Related articlesFree article

Methotrexate in inflammatory bowel disease.

Feagan BG, Alfadhli A.

Gastroenterol Clin North Am. 2004 Jun;33(2):407-20, xi. Review.PMID: 15177546 [PubMed - indexed for MEDLINE]Related articles

5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion.

Feagan BG.

Clin Gastroenterol Hepatol. 2004 May;2(5):376-8. No abstract available. PMID: 15118974 [PubMed - indexed for MEDLINE]Related articles

Infliximab maintenance therapy for fistulizing Crohn's disease.

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ.

N Engl J Med. 2004 Feb 26;350(9):876-85.PMID: 14985485 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.

Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB.

Gastroenterology. 2004 Feb;126(2):402-13.PMID: 14762776 [PubMed - indexed for MEDLINE]Related articles

Maintenance therapy for inflammatory bowel disease.

Feagan BG.

Am J Gastroenterol. 2003 Dec;98(12 Suppl):S6-S17. Review.PMID: 14697913 [PubMed - indexed for MEDLINE]Related articles

AGA technical review on perianal Crohn's disease.

Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee.

Gastroenterology. 2003 Nov;125(5):1508-30. Review. No abstract available. PMID: 14598268 [PubMed - indexed for MEDLINE]Related articles

The effects of infliximab maintenance therapy on health-related quality of life.

Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR.

Am J Gastroenterol. 2003 Oct;98(10):2232-8.PMID: 14572573 [PubMed - indexed for MEDLINE]Related articles

Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.

Sandborn WJ, Feagan BG.

Aliment Pharmacol Ther. 2003 Aug 1;18(3):263-77. Review.PMID: 12895211 [PubMed - indexed for MEDLINE]Related articlesFree article